ANTICANCER FUSION PROTEIN

ANTICANCER FUSION PROTEIN

A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: PIECZYKOLAN, JERZY SZCZEPAN, PAWLAK, SEBASTIAN, LEMKE, KRZYSZTOF KAZIMIERZ, ZEREK, BARTLOMIEJ
Format: Patent
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator PIECZYKOLAN, JERZY SZCZEPAN
PAWLAK, SEBASTIAN
LEMKE, KRZYSZTOF KAZIMIERZ
ZEREK, BARTLOMIEJ
description A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an immunostimulating effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_SG10201509676UA</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>SG10201509676UA</sourcerecordid><originalsourceid>FETCH-epo_espacenet_SG10201509676UA3</originalsourceid><addsrcrecordid>eNrjZJB09AvxdHb0c3YNUnALDfb091MICPIPcfX042FgTUvMKU7lhdLcDCpuriHOHrqpBfnxqcUFicmpeakl8cHuhgZGBoamBpZm5mahjsZEKgMA3fQhmQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ANTICANCER FUSION PROTEIN</title><source>esp@cenet</source><creator>PIECZYKOLAN, JERZY SZCZEPAN ; PAWLAK, SEBASTIAN ; LEMKE, KRZYSZTOF KAZIMIERZ ; ZEREK, BARTLOMIEJ</creator><creatorcontrib>PIECZYKOLAN, JERZY SZCZEPAN ; PAWLAK, SEBASTIAN ; LEMKE, KRZYSZTOF KAZIMIERZ ; ZEREK, BARTLOMIEJ</creatorcontrib><description>A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an immunostimulating effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.</description><language>eng</language><creationdate>2015</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20151230&amp;DB=EPODOC&amp;CC=SG&amp;NR=10201509676UA$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20151230&amp;DB=EPODOC&amp;CC=SG&amp;NR=10201509676UA$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>PIECZYKOLAN, JERZY SZCZEPAN</creatorcontrib><creatorcontrib>PAWLAK, SEBASTIAN</creatorcontrib><creatorcontrib>LEMKE, KRZYSZTOF KAZIMIERZ</creatorcontrib><creatorcontrib>ZEREK, BARTLOMIEJ</creatorcontrib><title>ANTICANCER FUSION PROTEIN</title><description>A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an immunostimulating effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2015</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJB09AvxdHb0c3YNUnALDfb091MICPIPcfX042FgTUvMKU7lhdLcDCpuriHOHrqpBfnxqcUFicmpeakl8cHuhgZGBoamBpZm5mahjsZEKgMA3fQhmQ</recordid><startdate>20151230</startdate><enddate>20151230</enddate><creator>PIECZYKOLAN, JERZY SZCZEPAN</creator><creator>PAWLAK, SEBASTIAN</creator><creator>LEMKE, KRZYSZTOF KAZIMIERZ</creator><creator>ZEREK, BARTLOMIEJ</creator><scope>EVB</scope></search><sort><creationdate>20151230</creationdate><title>ANTICANCER FUSION PROTEIN</title><author>PIECZYKOLAN, JERZY SZCZEPAN ; PAWLAK, SEBASTIAN ; LEMKE, KRZYSZTOF KAZIMIERZ ; ZEREK, BARTLOMIEJ</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_SG10201509676UA3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>online_resources</toplevel><creatorcontrib>PIECZYKOLAN, JERZY SZCZEPAN</creatorcontrib><creatorcontrib>PAWLAK, SEBASTIAN</creatorcontrib><creatorcontrib>LEMKE, KRZYSZTOF KAZIMIERZ</creatorcontrib><creatorcontrib>ZEREK, BARTLOMIEJ</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>PIECZYKOLAN, JERZY SZCZEPAN</au><au>PAWLAK, SEBASTIAN</au><au>LEMKE, KRZYSZTOF KAZIMIERZ</au><au>ZEREK, BARTLOMIEJ</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ANTICANCER FUSION PROTEIN</title><date>2015-12-30</date><risdate>2015</risdate><abstract>A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an immunostimulating effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_SG10201509676UA
source esp@cenet
title ANTICANCER FUSION PROTEIN
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T23%3A37%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=PIECZYKOLAN,%20JERZY%20SZCZEPAN&rft.date=2015-12-30&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ESG10201509676UA%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true